key: cord-1023005-zkqrrkh9 authors: Cai, Yuli; Shi, Shaobo; Yang, Fan; Yi, Bo; Chen, Xiaolin; Li, Junfeng; Wen, Zhongyuan title: Fasting blood glucose level is a predictor of mortality in patients with COVID-19 independent of diabetes history date: 2020-09-10 journal: Diabetes Res Clin Pract DOI: 10.1016/j.diabres.2020.108437 sha: e323ad9a74584604ed91f1c9f9c930db8e9cd41e doc_id: 1023005 cord_uid: zkqrrkh9 Aim No study elucidated the role of fasting blood glucose (FBG) level in the prognosis of coronavirus disease 2019 (COVID-19). Methods This cohort study was conducted in a single center at Renmin Hospital of Wuhan University, Wuhan, China. Clinical laboratory, and treatment data of inpatients with laboratory-confirmed COVID-19 were collected and analyzed. Outcomes of patients with and without pre-existing diabetes were compared. The associations of diabetes history and/or FBG levels with mortality were analyzed. Multivariate cox regression analysis on the risk factors associated with mortality in patients with COVID-19 was performed. Results A total of 941 hospitalized patients with COVID-19 were enrolled in the study. There was a positive relationship between pre-existing diabetes and the mortality of patients who developed COVID-19 (21 of 123 [17.1%] vs 76 of 818 [9.3%]; P =0.012). FBG≥7.0 mmol/L was an independent risk factor for the mortality of COVID-19 regardless of the presence or not of a history of diabetes (hazard ratio, 2.20 [95% CI, 1.21-4.03]; P =0.010). Conclusions We firstly showed FBG ≥7.0 mmol/L predicted worse outcome in hospitalized patients with COVID-19 independent of diabetes history. Our findings indicated screening FBG level is an effective method to evaluate the prognosis of patients with COVID-19. The COVID-19 pandemic, which caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a novel and serious global health threat and dramatically spreads worldwide [1] . Diabetes has been uniformly reported to be associated with poor prognosis in coronavirus infections. One retrospective analysis suggested that a known history of diabetes and ambient hyperglycemia were independent predictors for death and morbidity in SARS patients [2] . Diabetes was prevalent in approximately 50% of the patients with MERS-CoV in a systematic analysis of 637 cases [3] . Recent clinical studies confirmed diabetes as a major comorbidity of COVID-19 [4] [5] [6] [7] . Guo et al [8] and Dong et al [9] had investigated the correlation between diabetes history and prognosis of COVID-19, which analyzed 174 and 193 patients with COVID-19 respectively. However, no study focused on the direct correlation between fasting blood glucose (FBG) levels and the prognosis of COVID-19. Furthermore, whether diabetes history or blood glucose level is more important for mortality of patients with COVID-19 remains unclear. In the present research, we investigated the clinical characteristics of patients with coexistence of COVID-19 infection and diabetes, and examined the associations of 5 diabetes history and/or FBG levels with the mortality of COVID-19 in a selected cohort of patients in Wuhan, China. This is a retrospective, single center study at Renmin Hospital of Wuhan University in Wuhan, We obtained clinical, laboratory, radiological, treatment, and outcome data from patients' electronic medical records for hospitalized patients. All data were reviewed by two investigators (F.Y. and B.Y.). Patients' diabetes history information was collected, and FBG levels were measured on admission. The normal reference range of FBG in Renmin hospital of Wuhan University is 3.9-6.1mmol/L. As FBG≥ 7.0 mmol/l is one of diagnostic criterions of diabetes, we took 7.0 mmol/l as a cut-point for the FBG levels. Clinical data included symptoms and comorbidities. Laboratory assessments included complete blood count, creactive protein (CRP), procalcitonin (PCT), electrolytes, liver and renal function values. Acute respiratory distress syndrome (ARDS) was defined according to the Berlin definition [10] . Acute kidney injury was identified according to the Kidney Disease: Improving Global Outcomes definition [11] . To confirm COVID-19, the Viral Nucleic Acid Kit (Health, Ningbo, China) was used to extract nucleic acids from throat swab, nose swab, anal swab, or phlegm samples according to the kit instructions. A 2019-nCoV detection kit (Bioperfectus, Taizhou, China) was used to detect the ORF1ab gene (nCovORF1ab) and the N gene (nCoV-NP) according to the manufacturer's instructions using real-time RT-PCR [12] . An infection was considered as laboratoryconfirmed if the nCovORF1ab and nCoV-NP both showed positive results. Descriptive statistics were obtained for all study variables. All categorical variables were compared for the study outcome by using the Fisher's exact test, and continuous variables were compared using the Student t test or the Mann-Whitney U test, if appropriate. Continuous data are expressed as mean ± standard deviation (SD) or median (interquartile ranger, IQR). Categorical data were expressed as the counts and proportion. Survival curves were plotted using the Kaplan-Meier method. Univariate and multivariate cox regression models were used to determine the independent risk factors for death during hospitalization, with a time from admission to the end of follow-up. The cases missing biomarker data were excluded listwise with statistics software. Data were analyzed using SPSS 25.0 (IBM, Chicago, IL). Statistical charts were generated using Excel 2016, Graphpad Prism (Version 5.0, GraphPad Software) or Minitab (Version 18, Minitab statistical Software). For all the statistical analyses, p < 0.05 was considered significant. Supplementary Figure 1 On admission, in the overall study population of 941 patients, median (IQR) levels of FBG (6.5 Table 1 ). All patients were treated in isolation. The median duration from symptom onset to admission was 10 (IQR, 7-14) days. A total of 919 patients (97.7%) were treated with oxygen. The percentages of use of oxygen inhalation, noninvasive ventilation, and invasive mechanical ventilation were 85.0% (800 patients), 8 On Kaplan-Meier analysis, the mortality in patients with pre-existing diabetes was higher than that in patients without pre-existing diabetes ( Among diabetes subjects, the mortality in patients with FBG≥7.0mmol/L (15/75 [20%]) was higher than that in patients with FBG< 7.0mmol/L (6/48 [12.5%]), however, there was no significant difference after log-rank test (P=0.296) ( Figure 1C ). Among non-diabetes subjects, the mortality in patients with FBG≥7.0mmol/L was remarkably higher than that in patients with FBG< 7.0mmol/L (36/167 [21.6%] vs 40/651[6.1%]; P <0.001) ( Figure 1D ). We performed a contour plot to determine the relationship between levels of FBG or age and mortality. Overall, the death rate of older patients was higher, especially for the age was greater than 60 years old (Figure 2A ). For patients with history of diabetes, high mortality was much closely correlated with hyperglycemia ( Figure 2B ). For patients without diabetes, higher mortality was also, to certain extent, related with hyperglycemia ( Figure 2C ). (Table 3) . In this retrospective analysis, we found that there was a positive relationship between preexisting diabetes and the mortality of patients who developed COVID-19, however, the diabetes history was not an independent risk factor of death rate in patients with COVID-19. More importantly, the present study was the first to show that FBG≥7.0 mmol/L was a predictor of mortality in patients with COVID-19 independent of diabetes history. Besides that, patients with diabetes revealed senior age and much severer inflammatory responses, as well as increased incidences of comorbidities and complications compared with those without diabetes. When grouped by FBG levels, in addition to above difference, patients with FBG≥ 7.0 mmol/L required more treatment than patients with FBG< 7.0 mmol/L. It was reported that glucose control is associated with different outcomes in patients with COVID-19 and pre-existing diabetes [13] . A recent study, which included 47 patients, showed FBG associated with mortality rate in COVID-19 patients with diabetes [14] . Notably, the present study found that, not only among known diabetes patients, but also in all the in-hospital COVID-19 patients, FBG≥ 7.0 mmol/L was an independent risk factor of mortality in patients with COVID-19. Specifically, in patients without diabetes history, the death rate was elevated significantly in response to hyperglycemia. The reasons why hyperglycemia but not diabetes history serves as an independent factor of death rate in COVID-19 patients appear to be due to not only the mechanisms concerning the effects of hyperglycemia on inflammation and angiotensin-converting enzyme 2 (ACE2) expression, but also the effects of diabetesassociated multifactorial factors on contributing to death in COVID-19 patients. For instance, patients with diabetes and COVID-19 were older, and had more severe inflammation and comorbidities, including hypertension, coronary heart disease, chronic renal failure and chronic heart failure, which also affected the mortality rate of COVID-19. Given this, it is very likely that the role of diabetes history as an independent risk factor for the mortality of COVID-19 was superimposed by other factors. In addition, dissociation of hyperglycemia from diabetes history likely also negated the role of diabetes as an independent factor for death rate in COVID-19 patients. As supporting evidence, certain patients without diabetes history had developed acute stress hyperglycemia after infection of COVID-19 [15] . Our findings indicated that screening FBG level is an effective and simple method to evaluate the prognosis of patients with COVID-19, and intervention should be taken in time when patients with FBG≥ 7.0 mmol/L regardless of the presence or not of a history of diabetes. We did not analyze the exact relationship between hypoglycemia and mortality due to the patients with FBG<3.9 mmol/L were rare in the present study. Actually, in both diabetes and non-diabetes groups, the death rates were high at a lower level of FBG. It was worth noting that patients with hypoglycemia were very old, and probably had a few comorbidities. It demonstrated that hypoglycemia appeared to reflect a poor general health condition, rather than a direct cause of death [16] . There are some mechanisms that FBG≥7.0 mmol/L might play a role in COVID-19 infection and poor prognosis. Since immunity is the first line of defense against SARS-CoV-2, it appears that the disturbed immunity in patients with hyperglycemia allowed unhindered proliferation of the pathogen within the host [17] . Hyperglycemia inhibits neutrophil chemotaxis, decreases phagocytosis by neutrophils, macrophages, and monocytes, and impairs innate cell-mediated immunity [18] . In patients with COVID-19, the proportion of proinflammatory Th17 CD4+ T cells and cytokine levels were elevated whereas peripheral counts of CD4+ and CD8+ T cells were decreased [19] . As such, patients with hyperglycemia may display impaired anti-viral IFN responses and delayed activation of Th1/Th17, which contributed to hyperinflammatory response [19] . On the other hand, it has been reported that elevated blood glucose levels could directly increase glucose concentrations in airway secretion, which may undermine the defensive ability of airway epithelia [20] . Consistently, in the present study, the proportion of lymphocytes was declined and the CRP levels were increased in patients with diabetes. As substantial evidence, we revealed that the CRP level was a risk factor of the mortality in COVID-19. Moreover, CRP and PCT levels were elevated more significantly in patients with diabetes who developed COVID-19. The study by Guo et al also revealed that the serum levels of inflammation-related biomarkers such as IL-6 and CRP were significantly higher in COVID-19 patients with diabetes [8] . Accumulating evidence suggests that patients with severe COVID-19 have increased incidence of a cytokine storm syndrome, which would cause mortality [6, 21] . Due to exaggerated inflammatory responses, patients with hyperglycemia were more susceptible to cytokine storm, which appeared to lead to rapid deterioration of COVID-19. As the cellular receptor for SARS-CoV-2 [22] , ACE2 may also account for the association between diabetes and COVID-19. ACE2 is abundant in the type I and II alveolar epithelial cells, endothelial cells, kidney tubular epithelium, heart and pancreas [19] . Latest study confirmed human pancreatic beta cells are highly permissive to SARS-CoV-2 infection [23] . Furthermore, patients with diabetes were often treated with the pioglitazone and liraglutide to control glucose levels, which could upregulate ACE2 levels and facilitate SARS-CoV-2 uptake [24, 25] . This may explain, in part, increased risk of severe infection in patients with hyperglycemia. In addition, the clearance of SARS-CoV-2 was delayed in patients with hyperglycemia [26] . Because of this, it is plausible that patients with hyperglycemia are susceptible to SARS-CoV-2 infection. Although this study included a large number of patients, some limitations existed. Firstly, because of the logistical restriction at the onset of these emerging infections in Wuhan, some data were lacking from clinical examinations of patients in isolation ward or ICU, such as glycosylated hemoglobin levels and records of monitoring blood glucose during in-patients. Secondly, diabetes was not subtyped when patients admitted to hospital, and this may make the results less comprehensive. Finally, the number of COVID-19 infection worldwide is increasing rapidly, the current sample is relative small, and it is only a single center study. In order to avoid statistical bias, data from larger populations and multiple centers are warranted to further confirm the results of the present study. Although diabetes history was associated with the mortality of patients hospitalized with COVID-19, FBG ≥ 7.0 mmol/l was an independent risk factor for the death of COVID-19. Our Mortality was higher in patients with senior age. B. In diabetes group, mortality was higher in patients with hyperglycemia. C. In non-diabetes group, mortality was higher in patients with hyperglycemia and senior age. FBG, fasting blood glucose. A Novel Coronavirus from Patients with Pneumonia in China Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis Clinical Characteristics of Coronavirus Disease 2019 in China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China Diabetes is a risk factor for the progression and prognosis of COVID-19 Clinical characteristics and outcomes of patients with severe covid-19 with diabetes Acute respiratory distress syndrome: the Berlin Definition Improving Global Outcomes Chronic Kidney Hypoglycemia associated with hospitalization and adverse events in older people: population-based cohort study COVID-19, diabetes mellitus and ACE2: The conundrum COVID-19 and diabetes COVID-19 pandemic, coronaviruses, and diabetes mellitus Factors determining the appearance of glucose in upper and lower respiratory tract secretions Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis Hypertension and Diabetes Delay the Viral Clearance in COVID-19 Patients